These results showed that either the knockdown of FTO or the treatment with the FTO-specific inhibitor, FB23-2 significantly reduced the metastatic and proliferative abilities of GC cells, as revealed by Transwell assay and the formation of cell clones (Fig. 5A-D and S4). This evidence concerns the gene FTO and gastric cancer.